AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30616461 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 45
Study 29798418 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL‐11 treatment
Number of subjects: 78
Study 29798418 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemoradiotherapy
Number of subjects: 78
Study 24441395 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular individualized rehabilitation program (IG)
Number of subjects: 30
Study 24441395 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program (CG)
Number of subjects: 30
Study 23118268 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV)
Number of subjects: 780
Study 23118268 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (7vCRM)
Number of subjects: 780
Study 21649812 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil of lavender aroma exposure
Number of subjects: 30
Study 21649812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18317856 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 24
Study 18317856 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 24
Study 18317856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VCV and PCV
Number of subjects: 24
Study 16503773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 120
Study 16503773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% travoprost
Number of subjects: 120
Study 16503773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.004% bimatoprost
Number of subjects: 120
Study 16503773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 4, artificial tears)
Number of subjects: 120
Study 16808700 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive display
Number of subjects: 24
Study 16808700 — intervention group
Group type: COMPARATOR
Intervention: Customized leaflet
Number of subjects: 24
Study 11157688 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 2647
Study 11157688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2647
Study 9446392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free mesh-plug repair (Lichtenstein in Rutkow's modification)
Number of subjects: 100
Study 9446392 — intervention group
Group type: COMPARATOR
Intervention: Bassini procedure
Number of subjects: 100
Study 7936516 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg intravaginal prostaglandin E2 (PGE2) suppositories
Number of subjects: 80
Study 3585441 — intervention group
Group type: EXPERIMENTAL
Intervention: Adr 70 mg/m2 IV day 1 and every 3 weeks
Number of subjects: 316
Study 3585441 — intervention group
Group type: EXPERIMENTAL
Intervention: Adr 20 mg/m2 IV day 1, 2, and 3, and 15 mg/m2 IV day 8 and weekly thereafter
Number of subjects: 316
Study 3585441 — intervention group
Group type: EXPERIMENTAL
Intervention: Adr 60 mg/m2 IV day 1 and DTIC 250 mg/m2 days 1 to 5, repeated every 3 weeks
Number of subjects: 316
Study 3585441 — intervention group
Group type: COMPARATOR
Intervention: Adr weekly
Number of subjects: 316
Study 3585441 — intervention group
Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 316
Study 31189455 — intervention group
Group type: EXPERIMENTAL
Intervention: Students
Number of subjects: 646
Study 31189455 — intervention group
Group type: COMPARATOR
Intervention: Faculty and Staff
Number of subjects: 646
Study 29533252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy
Number of subjects: 32
Study 29533252 — intervention group
Group type: COMPARATOR
Intervention: Land-based aerobic exercise
Number of subjects: 32
Study 28625402 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based delivery of fluid paclitaxel after bare metal stenting (DDB+BMS group)
Number of subjects: 68
Study 28625402 — intervention group
Group type: COMPARATOR
Intervention: Drug eluting stent (DES group)
Number of subjects: 68
Study 28625402 — intervention group
Group type: COMPARATOR
Intervention: Everolimus eluting stent (EES subgroup)
Number of subjects: 68
Study 28625402 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel eluting stent (PES subgroup)
Number of subjects: 68
Study 28625402 — intervention group
Group type: EXPERIMENTAL
Intervention: DDB+BMS group
Number of subjects: 68
Study 28625402 — intervention group
Group type: COMPARATOR
Intervention: EES subgroup
Number of subjects: 68
Study 28625402 — intervention group
Group type: COMPARATOR
Intervention: PES subgroup
Number of subjects: 68
Study 26609037 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise and whole body vibration (WBV) training, 3 times a week for 10 weeks
Number of subjects: 34
Study 26609037 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine life)
Number of subjects: 34
Study 23390553 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering
Number of subjects: 11140
Study 23390553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood glucose control
Number of subjects: 11140
Study 21968667 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% oregano extract ointment
Number of subjects: 40
Study 21968667 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 40
Study 19009747 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon (8 MIU every other day for 2 years)
Number of subjects: 58
Study 19009747 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon
Number of subjects: 58
Study 16817643 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily activities (sitting, walking, running, jumping)
Number of subjects: 0
Study 12838499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) combined with cyclosporine (CSA) and prednisone
Number of subjects: 100000
Study 12838499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus compared with cyclosporine (CSA)
Number of subjects: 100000
Study 12838499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus in combination with MMF
Number of subjects: 100000
Study 12838499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 100000
Study 12838499 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy with MMF
Number of subjects: 100000
Study 12838499 — intervention group
Group type: EXPERIMENTAL
Intervention: Common complications (chronic allograft nephropathy, hypertension, hyperlipidemia, bone disease)
Number of subjects: 100000
Study 10714836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body forced air warming
Number of subjects: 26
Study 10714836 — intervention group
Group type: COMPARATOR
Intervention: Upper body forced air warming
Number of subjects: 26
Study 10714836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both upper and lower body forced air warming
Number of subjects: 26
Study 9363861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-course 5-FU plus l-leucovorin with I.V. leucovorin (100 mg/m2)
Number of subjects: 926
Study 9363861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-course 5-FU plus oral (d,l)-leucovorin (125 mg/m2)
Number of subjects: 926
Study 9363861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-course 5-FU plus I.V. (d,l)-leucovorin (200 mg/m2)
Number of subjects: 926
Study 9363861 — intervention group
Group type: COMPARATOR
Intervention: Overall response rate for patients with measurable disease
Number of subjects: 926
Study 9363861 — intervention group
Group type: COMPARATOR
Intervention: Grade III to IV toxic effects
Number of subjects: 926
Study 8239918 — intervention group
Group type: EXPERIMENTAL
Intervention: Vratizolin (3% hydrophilic cream or ointment, four times daily)
Number of subjects: 193
Study 8239918 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (zinc ointment, Aphtin, Oxycort, Dicortinef)
Number of subjects: 193
Study 3699121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol powder inhaler with fast inhalation (16-19 l/min)
Number of subjects: 10
Study 3699121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol powder inhaler with breath-holding pause of 10 seconds
Number of subjects: 10
Study 3699121 — intervention group
Group type: COMPARATOR
Intervention: Normal children (150 children aged 3.5-15 years)
Number of subjects: 10
Study 29514921 — intervention group
Group type: EXPERIMENTAL
Intervention: High Physical and Sexual Violence and Injuries class
Number of subjects: 947
Study 29514921 — intervention group
Group type: EXPERIMENTAL
Intervention: High Physical and Low Sexual Violence and Injuries class
Number of subjects: 947
Study 29514921 — intervention group
Group type: COMPARATOR
Intervention: Low Physical and Sexual Violence class
Number of subjects: 947
Study 29514921 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall working women reporting work-related disruption due to IPV
Number of subjects: 947
Study 27166242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 13
Study 27166242 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 13
Study 27166242 — intervention group
Group type: COMPARATOR
Intervention: Control condition (NN)
Number of subjects: 13
Study 24725808 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol 500 mg
Number of subjects: 12
Study 24725808 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol 1000 mg
Number of subjects: 12
Study 24725808 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol 2000 mg
Number of subjects: 12
Study 24725808 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol (all doses)
Number of subjects: 12
Study 23740460 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL19 levels in RA patients
Number of subjects: 208
Study 23740460 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL13 levels in RA patients
Number of subjects: 208
Study 23740460 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine levels in RA patients
Number of subjects: 208
Study 20834165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum No. 14 (LP14) at a dosage of 8.7×10(8)
Number of subjects: 0
Study 20834165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20834165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum No. 14 (LP14)
Number of subjects: 0
Study 17689732 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.)
Number of subjects: 48
Study 17689732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15842286 — intervention group
Group type: EXPERIMENTAL
Intervention: PgE(2) 1 mg
Number of subjects: 332
Study 15842286 — intervention group
Group type: EXPERIMENTAL
Intervention: PgE(2) 2 mg
Number of subjects: 332
Study 15842286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 15842286 — intervention group
Group type: EXPERIMENTAL
Intervention: PgE(2) groups
Number of subjects: 332
Study 15842286 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and neonatal morbidity
Number of subjects: 332
Study 11831913 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'7'‐bis‐(2‐carboxyethyl)‐5‐(and‐6)‐carboxyfluorescein, acetoxymethyl ester (80 microg) applied via subconjunctival injection 15 minutes prior to trabeculectomy, followed by intraoperative illumination with diffuse blue light (450‐490 nm) for 8 minutes
Number of subjects: 10
Study 11831913 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 10980843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study 10980843 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 8613282 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg daily for 5 days
Number of subjects: 62
Study 8613282 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 7.5 mg/kg thrice daily for 5 days
Number of subjects: 62
Study 2125241 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil infusion (0.03 mg/kg bolus followed by continuous infusion at 0.02 mg/kg/h for the first 24 hours and 0.03 mg/kg/h for the last 48 hours)
Number of subjects: 9
Study 2125241 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil infusion
Number of subjects: 9
Study 2125241 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil withdrawal
Number of subjects: 9
Study 161694 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen given I.V. at birth
Number of subjects: 500
Study 161694 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase activated human plasmin
Number of subjects: 500
Study 161694 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen recipient group
Number of subjects: 500
Study 161694 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmin inhibitors measured with a functional assay
Number of subjects: 500
Study 30284385 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine-A 2% eye drops
Number of subjects: 33
Study 30284385 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eye drops
Number of subjects: 33
Study 28359309 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 144
Study 28359309 — intervention group
Group type: COMPARATOR
Intervention: Placebo electroacupuncture
Number of subjects: 144
Study 26530718 — intervention group
Group type: EXPERIMENTAL
Intervention: JinQi Jiangtang tablets
Number of subjects: 400
Study 26530718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 23302358 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils‐containing antiseptic mouthrinse
Number of subjects: 139
Study 23302358 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinsing
Number of subjects: 139
Study 21070228 — intervention group
Group type: COMPARATOR
Intervention: Topiramate plus placebo injections
Number of subjects: 59
Study 21070228 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injections plus placebo tablets
Number of subjects: 59
Study 19577745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol lavage
Number of subjects: 42
Study 19577745 — intervention group
Group type: COMPARATOR
Intervention: Saline solution lavage
Number of subjects: 42
Study 19577745 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 42
Study 17645403 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention (patient and physician education)
Number of subjects: 13455
Study 17645403 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 13455
Study 10925503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic veneer restorations with coronal height reduced to 7.5 mm (Group A)
Number of subjects: 48
Study 10925503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic veneer restorations with coronal height reduced to 6.5 mm (Group B)
Number of subjects: 48
Study 10925503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic veneer restorations with coronal height reduced to 5.5 mm (Group C)
Number of subjects: 48
Study 10925503 — intervention group
Group type: COMPARATOR
Intervention: Experimental control with coronal height of 8.5 mm (Group D)
Number of subjects: 48
Study 10925503 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent group with intact incisal edge of enamel (Group E)
Number of subjects: 48
Study 8810653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (single oral dose)
Number of subjects: 12
Study 8810653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (chronic phase)
Number of subjects: 12
Study 8810653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1578085 — intervention group
Group type: COMPARATOR
Intervention: One true modified ECT followed by five sham ECTs
Number of subjects: 24
Study 1578085 — intervention group
Group type: EXPERIMENTAL
Intervention: Six true ECTs
Number of subjects: 24
Study 3868306 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectally administered diazepam (0.6 mg/kg)
Number of subjects: 12
Study 3868306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31258108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (780 mg/d for 7 days)
Number of subjects: 34
Study 31258108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31258108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose and Placebo (combined analysis)
Number of subjects: 34
Study 29239260 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 100
Study 29239260 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush
Number of subjects: 100
Study 27901245 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at 2 mA, with the cathode positioned in the supplementary motor cortex and the anode in the deltoid, applied for 4 weeks.
Number of subjects: 44
Study 27901245 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (control group).
Number of subjects: 44
Study 25311296 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (including selective estrogen receptor modulators, selective estrogen receptor downregulators, and aromatase inhibitors)
Number of subjects: 0
Study 25311296 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting other components of pathologically activated intracellular signaling
Number of subjects: 0
Study 22763312 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib
Number of subjects: 60
Study 22763312 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 60
Study 20543728 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second massage
Number of subjects: 10
Study 20543728 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-second massage
Number of subjects: 10
Study 20543728 — intervention group
Group type: COMPARATOR
Intervention: No massage (control)
Number of subjects: 10
Study 17299460 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine serum concentrate (BSC)
Number of subjects: 4
Study 17299460 — intervention group
Group type: COMPARATOR
Intervention: Whey protein concentrate (WPC, control group)
Number of subjects: 4
Study 17299460 — intervention group
Group type: EXPERIMENTAL
Intervention: WPC+MMN
Number of subjects: 4
Study 17299460 — intervention group
Group type: EXPERIMENTAL
Intervention: BSC+MMN
Number of subjects: 4
Study 15963128 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 41
Study 15963128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent self-catheterization (CISC)
Number of subjects: 41
Study 15963128 — intervention group
Group type: COMPARATOR
Intervention: Control group (CISC)
Number of subjects: 41
Study 15963128 — intervention group
Group type: COMPARATOR
Intervention: Both CISC and immediate TURP
Number of subjects: 41
Study 12889587 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine contraction frequency measurement
Number of subjects: 306
Study 10537440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine-containing regimens
Number of subjects: 0
Study 10537440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine regimen
Number of subjects: 0
Study 10537440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine therapy
Number of subjects: 0
Study 8945073 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (450 or 600 mg)
Number of subjects: 283
Study 8945073 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (1 mg) or Placebo
Number of subjects: 283
Study 1769127 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 2 IU/m2 subcutaneously daily for 4 months
Number of subjects: 20
Study 1769127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30871498 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-care intervention
Number of subjects: 74
Study 29270641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (low, medium, high doses)
Number of subjects: 16
Study 29270641 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (low, medium, high doses)
Number of subjects: 16
Study 29270641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29270641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 16
Study 29270641 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration
Number of subjects: 16
Study 26613620 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily meal delivery
Number of subjects: 626
Study 26613620 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly meal delivery
Number of subjects: 626
Study 26613620 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 626
Study 23944355 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (6 × 10 min runs at 70% of peak oxygen uptake)
Number of subjects: 14
Study 23944355 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive on day 1)
Number of subjects: 14
Study 23944355 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 14
Study 22054056 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt sheet
Number of subjects: 30
Study 22054056 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 30
Study 20418657 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF PrP(C) levels in spinal cord injured patients 12 hours after injury
Number of subjects: 0
Study 20418657 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF PrP(C) levels in spinal cord injured patients 7 days after injury
Number of subjects: 0
Study 18380554 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF+R
Number of subjects: 19
Study 18380554 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 19
Study 15995948 — intervention group
Group type: EXPERIMENTAL
Intervention: M01ZH09 with prevaccination with a bicarbonate buffer (presentation 1)
Number of subjects: 32
Study 15995948 — intervention group
Group type: EXPERIMENTAL
Intervention: M01ZH09 without prevaccination with a bicarbonate buffer (presentation 2)
Number of subjects: 32